Pfizer on Paxlovid: 'Our anti-Covid pill also effective against Omicron variant'
US pharmaceutical company Pfizer on Omicron variant: ‘Paxlovid prevents severe disease’
Covid variant Omicron, the effectiveness of Pfizer’s Paxlovid
“A Pfizer study on the anti-Covid pill confirms the drug’s effectiveness in preventing severe disease.
The pill, from laboratory studies, is effective against the Omicron variant”.
Thus the American company Pfizer in a note concerning the Omicron variant
Albert Bourla, chief executive of Pfizer, also said: “We are confident that, if licensed or approved, this pill could be a decisive tool in fighting the pandemic.
Paxlovid, the drug’s commercial name, “must be administered in the first three days after the onset of symptoms and reduces hospitalisations and death by 89%”, the pharmaceutical company noted in today’s announcement.
Read Also:
Omicron Variant: What Is It And What Are The Symptoms Of The Infection?
Covid, Cooke (Ema): ‘We Have Contingency Plans For Omicron Variant’
Covid, Experts In Japan Confirm: ‘Omicron More Contagious But Symptoms Milder’